Clinical TrialJun 29, 2026, 04:07 PM
Polyrizon Gets Central IRB Approval for Allergy Blocker Clinical Trial
AI Summary
Polyrizon Ltd. announced it has received central Institutional Review Board (IRB) approval to commence its first human clinical trial for NASARIX™, an innovative nasal spray designed to block airborne allergens. This approval from BRANY Institutional Review Board, granted on June 18, 2026, is a key regulatory milestone, confirming the study protocol and patient protection requirements are met. The trial will evaluate the efficacy, safety, and tolerability of NASARIX™ in patients with seasonal allergic rhinitis.
Key Highlights
- Polyrizon received central IRB approval for its NASARIX™ allergy blocker clinical trial.
- Approval was granted by BRANY Institutional Review Board on June 18, 2026.
- The study will evaluate the efficacy, safety, and tolerability of NASARIX™ in patients with seasonal allergic rhinitis.
- NASARIX™ will be compared against a saline spray control to assess symptom relief and patient outcomes.
- The approval covers the master protocol, informed consent, and other study documentation.
- Site-specific IRB approvals are still required before patient enrollment can begin.
- The central IRB approval is valid through June 17, 2027.
Price Impact
More from PLRZ